MyFinsight
Home
Blog
About
ZyVersa Therapeutics, Inc. (ZVSA)
ZyVersa Therapeutics, Inc. (ZVSA)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$200,882
Unit: Dollar
Positive Cash Flow Breakdown
Proceeds from issuance of conver...
Accrued expenses and other curre...
Fair value option loss on conver...
Others
Negative Cash Flow Breakdown
Net loss
Prepaid expenses and other curre...
Change in fair value of warrant ...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Non-cash rent expense
-
0
-
0
Operating lease liability
-
0
-
0
Depreciation of fixed assets
-
0
-
0
Net loss
-1,793,381
-678,572
-19,805,559
-4,468,247
Impairment of in-process research and development
-
0
18,647,903
-
Stock-based compensation
55,872
17,353
73,988
131,490
Issuance of common stock pursuant to vendor agreements
-
0
29,600
210,400
Fair value option loss on convertible notes
-344,000
-
-
-
Write-off of deferred offering costs
-
57,238
-
-
Change in fair value of equity payable
28,171
-
-
-
Deferred tax (benefit) provision
-
0
-851,659
0
Change in fair value of warrant liabilities
-16,000
-
-
-
Prepaid expenses and other current assets
92,374
-66,553
-80,557
193,876
Vendor deposits
14,484
154,879
-1,652
8,700
Accounts payable
111,885
318,262
314,798
56,208
Accrued expenses and other current liabilities
548,225
-349,402
105,112
961,545
Net cash used in operating activities
-799,118
-413,689
-1,406,912
-3,293,780
Exercise of warrants
-
0
-
0
Payment of offering costs
-
-12,511
12,511
-
At the market issuance of stock proceeds
-
0
-
-
Private placement of warrants
-
0
0
1,999,791
Warrant inducement offer - exercise proceeds
-
0
2,051,852
-
Deferred offering costs
-
-
-
17,928
Exercise of pre-funded warrants
-
0
0
210
Registration and issuance costs associated with warrant issuance
-
0
219,487
147,131
Proceeds from issuance of convertible notes and warrants
1,000,000
-
-
-
Net cash provided by financing activities
1,000,000
-12,511
1,862,804
1,834,942
Net increase in cash
200,882
-426,200
455,892
-1,458,838
Cash - beginning of period
101,778
527,978
1,530,924
-
Cash - end of period
302,660
101,778
527,978
-
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
convertible notes and...
$1,000,000
Net cash provided by
financing activities
$1,000,000
Net increase in cash
$200,882
Canceled cashflow
$799,118
Accrued expenses and
other current...
$548,225
Fair value option
loss on convertible...
-$344,000
Accounts payable
$111,885
Stock-based compensation
$55,872
Change in fair value of
equity payable
$28,171
Vendor deposits
$14,484
Net cash used in
operating activities
-$799,118
Canceled cashflow
$1,102,637
Net loss
-$1,793,381
Prepaid expenses and
other current assets
$92,374
Change in fair value of
warrant liabilities
-$16,000
Buy us a coffee